title: Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel.
authors.forename: Frederic R
authors.initials: FR
authors.lastname: Curtiss
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Fairman
mesh_terms: D000077144:Clopidogrel; D003132:Commerce / Q000639:trends; D016527:Drug Costs; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics / Q000639:trends; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000191:economics* / Q000627:therapeutic use; D013927:Thrombosis / Q000191:economics / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
chemical_list: D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine